Skip to main content
Elizabeth Buchbinder, MD, Oncology, Boston, MA

ElizabethIBuchbinderMD

Oncology Boston, MA

Hematologic Oncology, Melanoma

Instructor in Medicine, Dana Farber Cancer Institute

Dr. Buchbinder is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Buchbinder's full profile

Already have an account?

  • Office

    Dana Farber Cancer Institute
    450 Brookline Avenue
    Boston, MA 02115
    Phone+1 617-632-5055

Summary

  • Dr. Elizabeth Buchbinder is an oncologist in Boston, MA and is affiliated with multiple hospitals in the area, including Dana-Farber Cancer Institute and Brigham and Women's Hospital. She received her medical degree from Tufts University School of Medicine and has been in practice 13 years. She specializes in hematologic oncology and melanoma and is experienced in melanoma and cutaneous malignancies.

Education & Training

  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
  • Beth Israel Deaconess Medical Center
    Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2004 - 2007
  • Tufts University School of Medicine
    Tufts University School of MedicineClass of 2004

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2024 - 2026
  • RI State Medical License
    RI State Medical License 2022 - 2026
  • MA State Medical License
    MA State Medical License 2006 - 2025
  • NH State Medical License
    NH State Medical License 2023 - 2025
  • CT State Medical License
    CT State Medical License 2022 - 2024
  • ME State Medical License
    ME State Medical License 2022 - 2024
  • VT State Medical License
    VT State Medical License 2022 - 2024
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Prognostic Gene Expression Profiling in Cutaneous Melanoma  
    Douglas Grossman, Sancy A Leachman, Larissa Korde, Elizabeth I Buchbinder, Emily Y Chu, Julia A Curtis, Laura K Ferris, Kenneth F Grossmann, Siwen Hu-Lieskovan, Joanne..., JAMA Dermatology

Lectures

  • Characterization of the genetics of mucosal melanoma in patients treated with immunotherapy. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Authored Content

  • Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
  • Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020
  • Prognostic Gene Expression Profiling in Cutaneous MelanomaJuly 2020

Press Mentions

  • Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024
    Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024September 11th, 2024
  • Neoadjuvant Immunotherapy Improves Outlook in High-Risk Melanoma
    Neoadjuvant Immunotherapy Improves Outlook in High-Risk MelanomaFebruary 24th, 2023
  • Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-Targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors
    Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-Targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid TumorsJanuary 17th, 2023
  • Join now to see all